STOCK TITAN

Invitae Corporation - NVTA STOCK NEWS

Welcome to our dedicated page for Invitae Corporation news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on Invitae Corporation stock.

Invitae Corporation (NVTA) delivers cutting-edge genetic diagnostics through advanced machine learning and digital health solutions. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's developments in precision medicine.

Access official press releases, financial announcements, and operational updates in one centralized location. Track NVTA's progress in genetic testing innovation, including advancements in hereditary disorder diagnostics, strategic partnerships, and regulatory milestones.

Our curated collection features earnings reports, clinical trial updates, technology breakthroughs, and executive leadership changes. All content is sourced directly from company filings and verified industry publications to ensure reliability.

Bookmark this page for streamlined access to Invitae's latest developments in genomic medicine. Stay informed about NVTA's role in transforming healthcare through their evidence-based approach to genetic data interpretation and diagnostic accessibility.

Rhea-AI Summary
Labcorp, a global leader in laboratory services, has won the bid for select assets of Invitae, a medical genetics company. The transaction, awaiting court approval on May 6, 2024, is valued at $239 million and is expected to generate $275-$300 million in annual revenue, primarily in oncology and rare diseases testing. The deal is set to close in the third quarter of 2024, pending regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Invitae, a leading medical genetics company, has entered into an agreement with Labcorp for the sale of its business. Labcorp, a global leader in laboratory services, has been selected as the winning bidder in a court-supervised sale process under Section 363 of the U.S. Bankruptcy Code. The $239 million cash bid includes the acquisition of substantially all of Invitae's assets, ensuring business continuity for customers, partners, and employees. The sale is subject to court and regulatory approvals, with completion expected in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Invitae, a leading medical genetics company, published its 2024 Environmental, Social and Governance (ESG) Report detailing its commitment to improving healthcare through genetic information. The report highlights achievements in patient access, genetic insights, product quality, and environmental sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Invitae (NVTA) announces new studies to be presented at the American Society of Breast Surgeons Annual Meeting, highlighting the role of machine learning in reducing variants of uncertain significance (VUS) in genetic testing for breast cancer patients. The research shows machine learning models can benefit underrepresented populations, resulting in more definitive genetic testing outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70%
Tags
none
-
Rhea-AI Summary
Invitae launches Clinical Variant Modeling to reduce variants of uncertain significance, providing more definitive answers for patients. The innovative approach leverages clinical information to improve variant classification and reduce VUS, benefiting nearly 45,000 patients initially.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
none
-
Rhea-AI Summary
Invitae (NVTA) announces estimated unaudited financial results for Q4 and FY 2023, showing revenue growth, gross profit increase, and cash burn details. Q4 revenue up 4% to $127.8 million, with GAAP gross profit at $74.1 million. FY 2023 revenue at $487.0 million, down 6% YoY, but non-GAAP gross profit increased to $254.2 million. Cash burn details and caution on unaudited data provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
Rhea-AI Summary
Invitae introduces Invitae Generation™, a high-quality variant detection and classification platform, at the 2024 ACMG Annual Clinical Genetics Meeting. The platform showcases the company's commitment to innovation and excellence in genetic variant testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
conferences
-
Rhea-AI Summary
Invitae (NVTA) files for voluntary chapter 11 protection to manage costs and improve business structure. The company plans to operate using its cash on hand and continue serving customers and patients. Senior noteholders support the sale process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.67%
Tags
none
-
Rhea-AI Summary
Invitae (NVTA) announces a partnership with BridgeBio Pharma (BBIO) to advance genetics-based drug discovery for rare diseases. The collaboration aims to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Invitae's extensive dataset and analytical capabilities will be combined with BridgeBio's expertise in rare disease research and therapeutic development to support the development of transformative medicines for patients with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Invitae Corporation

NYSE:NVTA

NVTA Rankings

NVTA Stock Data

5.59M
284.38M
1.51%
47.96%
23.65%
Diagnostics & Research
Healthcare
Link
United States
San Francisco